[Dyskinesia in Parkinson's disease--major clinical features, aetiology, therapy].
Parkinson's disease (PD), a slowly, progressive degenerative disorder of the central nervous system, which affects about ten million people world-wide, is currently treated symptomatically. Current treatment aim i. e. to balance the decreased dopamine turnover in striatal neurons. Chronic exposure to dopaminergic agents, however, supports onset of motor complications and dyskinesia in the long term. Dyskinesia appear mainly as chorea, athetosis, dystonia, stereotypia, ballism or a combination. Sometimes excessive abnormal facial, body and limb movements depend on the overall dosage of dopaminergic substitution. This is why the main therapy is based on reducing the total dosage of dopaminergic substances. Either alternative or additional well-tried substances like apomorphine, amantadine or clozapine are used. New possibilities in treatment emerge from substances like sarizotan, istradefylline, fipampezol or talampanel. Even so disability and reduced quality of life in PD patients and their caregivers may exist. This survey describes the major clinical features, aetiology and demographics of treatment-associated dyskinesia in PD.
Ellrichmann
G
G
Neurologische Klinik im St. Josef-Hospital, Ruhr Universität Bochum. gisa.ellrichmann@rub.de
Russ
H
H
Müller
T
T
D000978:Antiparkinson Agents / Q000627:therapeutic use; D001479:Basal Ganglia / Q000503:physiopathology; D020820:Dyskinesias / Q000191:economics / Q000453:epidemiology / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D018696:Neuroprotective Agents / Q000627:therapeutic use; D019635:Neurosurgical Procedures; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy*; D011788:Quality of Life; D012307:Risk Factors
D000978:Antiparkinson Agents; D018696:Neuroprotective Agents; D007980:Levodopa